Chengdu-Based WestGene Biopharma Files for IPO Following Landmark mRNA Technology Outbound Deal

Jun 12, 2026 14:07 CST Updated 14:07

Cartesian Therapeutics

Pharmaceutical R&D Developer

Note: This article does not constitute any investment advice or recommendations; please refer to official/company announcements for authoritative information. This article is intended solely for the introduction of medications related to medical health and does not recommend treatment plans (if involved), nor does it represent the platform's position.Authorization is required for any article reprints.

On June 9, 2026, a cross-Pacific strategic partnership was officially finalized. Chengdu Weisijin Biotech and Nasdaq-listed Cartesian Therapeutics (NASDAQ: RNAC) announced a strategic collaboration and licensing agreement to jointly develop in vivo CAR-T and T-cell engager (TCE) therapies based on mRNA and targeted lipid nanoparticle (tLNP) technologies for the treatment of autoimmune diseases.

This is a typical “technology-complementary” deal—Wisentz contributes its delivery platform, while Cartesian Therapeutics provides CAR payloads, with both parties bringing technologies that have been clinically validated in humans. Behind this transaction lies an industry-wide shift in the in vivo CAR-T sector, which has leaped from proof-of-concept to clinical competition in just two years.

Pursuant to the terms of the agreement, for each collaborative project, Wisgen Biotech will receive an upfront payment, as well as development, regulatory, and commercialization milestone payments. In addition, Wisgen Biotech will share in potential future sublicense revenues and product sales royalties.

The giants have entered the fray

The fervor in the in vivo CAR-T sector is evident from the M&A transactions over the past two years.

June 2025,AbbVieAcquired Capstan for $2.1 billion, betting on the potential of its core pipeline candidate CPTX-2309 in the autoimmune field; in October,BMSAcquired Orbital for $1.5 billion; its core product, OTX-201, has reached the IND application stage for the treatment of autoimmune diseases; February 2026,Eli LillyAcquired Orna for $2.4 billion, whose core pipeline also features in vivo CD19 CAR-T therapies for autoimmune diseases. These three transactions, totaling over $6 billion, are all directed toward in vivo CAR-T therapies in the autoimmune field.

Clinical data are also accelerating to confirm this.。

At the 2026 ASCO Annual Meeting, Kelonia’s KLN-1010 achieved a 100% objective response rate and MRD negativity in patients with multiple myeloma;Legend BiotechThe in vivo CAR-T LB2501 achieved a 100% objective response rate and an 83.3% complete response rate in the second dose-level cohort;Qihan BiologicsIn vivo CAR-T therapy also achieves rapid complete remission in patients with multiple myeloma. The intensive readout of clinical data is propelling in vivo CAR-T from “proof-of-concept” to a “clinical race.”

In terms of the technical routeLeveraging advantages such as transient expression, repeatable dosing, and non-integrating safety profiles, the mRNA/LNP platform has emerged as the mainstream choice for in vivo CAR-T therapies. Among the 42 in vivo CAR-T pipelines disclosed at this year’s ASGCT Annual Meeting, nearly 50% adopted the mRNA/LNP approach. The transaction between WestGene and Cartesian Therapeutics precisely represents the “first-half assembly” within this technological trajectory.

In VivoThe core of competition in the CAR-T sector will revolve aroundThree DimensionsExpand:Precision and efficiency of delivery, intensity and durability of CAR expression, and safety window in autoimmune diseases. The combination of Weizhi and Cartesian Therapeutics is supported by human data in the first dimension, leverages Cartesian’s clinically validated payload in the second dimension, and benefits from the inherent advantages of the mRNA approach in the third dimension.

References:

Company Website

Scan the QR code to join the group

Master CAR-T therapy, stem cell therapy, geneTherapy,Comprehensive Information on Oncolytic Viruses and Nucleic Acid Therapeutics